Fang Yuan1,2, Lili Jiang1, Qianyang Li1, Leon Sokulsky3, Yuanyuan Wanyan1, Lingli Wang1, Xiaojie Liu1, Lujia Zhou1, Hock L Tay3, Guojun Zhang4, Ming Yang1,3, Fuguang Li1. 1. Academy of Medical Sciences and Department of Immunology, College of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China. 2. Department of Medical Laboratory, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China. 3. Priority Research Centre for Healthy Lungs, Faculty of Health and Hunter Medical Research Institute, School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, Australia. 4. Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Abstract
Background: The anti-inflammatory effect of an α7nAChR agonist, PNU-282987, has previously been explored in the context of inflammatory disease. However, the effects of PNU-282987 on type 2 innate lymphoid cells (ILC2s)-mediated allergic airway inflammation has not yet been established. Aims: To determine the effects of PNU-282987 on the function of ILC2s in the context of IL-33- or Alternaria Alternata (AA)- induced airway inflammation. Methods: PNU-282987 was administered to mice that received recombinant IL-33 or AA intranasal challenges. Lung histological analysis and flow cytometry were performed to determine airway inflammation and the infiltration and activation of ILC2s. The previously published α7nAChR agonist GTS-21 was employed as a comparable reagent. ILC2s were isolated from murine lung tissue and cultured in vitro in the presence of IL-33, IL-2, and IL-7 with/without either PNU-282987 or GTS-21. The expression of the transcription factors GATA3, IKK, and NF-κB were also determined. Results: PNU-282987 and GTS-21 significantly reduced goblet cell hyperplasia in the airway, eosinophil infiltration, and ILC2s numbers in BALF, following IL-33 or AA challenge. In vitro IL-33 stimulation of isolated lung ILC2s showed a reduction of GATA3 and Ki67 in response to PNU-282987 or GTS-21 treatments. There was a significant reduction in IKK and NF-κB phosphorylation in the PNU-282987-treated group when compared to the GTS-21-treated ILC2s. Conclusion: PNU-282987 inhibits ILC2-associated airway inflammation, where its effects were comparable to that of GTS-21.
Background: The anti-inflammatory effect of an α7nAChR agonist, PNU-282987, has previously been explored in the context of inflammatory disease. However, the effects of PNU-282987 on type 2 innate lymphoid cells (ILC2s)-mediated allergic airway inflammation has not yet been established. Aims: To determine the effects of PNU-282987 on the function of ILC2s in the context of IL-33- or Alternaria Alternata (AA)- induced airway inflammation. Methods:PNU-282987 was administered to mice that received recombinant IL-33 or AA intranasal challenges. Lung histological analysis and flow cytometry were performed to determine airway inflammation and the infiltration and activation of ILC2s. The previously published α7nAChR agonist GTS-21 was employed as a comparable reagent. ILC2s were isolated from murine lung tissue and cultured in vitro in the presence of IL-33, IL-2, and IL-7 with/without either PNU-282987 or GTS-21. The expression of the transcription factors GATA3, IKK, and NF-κB were also determined. Results:PNU-282987 and GTS-21 significantly reduced goblet cell hyperplasia in the airway, eosinophil infiltration, and ILC2s numbers in BALF, following IL-33 or AA challenge. In vitro IL-33 stimulation of isolated lung ILC2s showed a reduction of GATA3 and Ki67 in response to PNU-282987 or GTS-21 treatments. There was a significant reduction in IKK and NF-κB phosphorylation in the PNU-282987-treated group when compared to the GTS-21-treated ILC2s. Conclusion:PNU-282987 inhibits ILC2-associated airway inflammation, where its effects were comparable to that of GTS-21.
Authors: Alice L Bodnar; Luz A Cortes-Burgos; Karen K Cook; Dac M Dinh; Vincent E Groppi; Mihaly Hajos; Nicole R Higdon; William E Hoffmann; Raymond S Hurst; Jason K Myers; Bruce N Rogers; Theron M Wall; Mark L Wolfe; Erik Wong Journal: J Med Chem Date: 2005-02-24 Impact factor: 7.446
Authors: Daniel R Neill; See Heng Wong; Agustin Bellosi; Robin J Flynn; Maria Daly; Theresa K A Langford; Christine Bucks; Colleen M Kane; Padraic G Fallon; Richard Pannell; Helen E Jolin; Andrew N J McKenzie Journal: Nature Date: 2010-03-03 Impact factor: 49.962
Authors: Mario B Marrero; Rudolf Lucas; Christina Salet; Terry A Hauser; Anatoly Mazurov; Patrick M Lippiello; Merouane Bencherif Journal: J Pharmacol Exp Ther Date: 2009-09-28 Impact factor: 4.030
Authors: David J Jackson; Heidi Makrinioti; Batika M J Rana; Betty W H Shamji; Maria-Belen Trujillo-Torralbo; Joseph Footitt; Aurica G Telcian; Alexandra Nikonova; Jie Zhu; Julia Aniscenko; Leila Gogsadze; Eteri Bakhsoliani; Stephanie Traub; Jaideep Dhariwal; James Porter; Duncan Hunt; Toby Hunt; Trevor Hunt; Luminita A Stanciu; Musa Khaitov; Nathan W Bartlett; Michael R Edwards; Onn Min Kon; Patrick Mallia; Nikolaos G Papadopoulos; Cezmi A Akdis; John Westwick; Matthew J Edwards; David J Cousins; Ross P Walton; Sebastian L Johnston Journal: Am J Respir Crit Care Med Date: 2014-12-15 Impact factor: 21.405
Authors: Luke B Roberts; Rita Berkachy; Madina Wane; Dhiren F Patel; Corinna Schnoeller; Graham M Lord; Kleoniki Gounaris; Bernhard Ryffel; Valerie Quesniaux; Matthew Darby; William G C Horsnell; Murray E Selkirk Journal: Front Immunol Date: 2022-05-27 Impact factor: 8.786